Comprehensive mastocytosis data analysis from a single center
Open Access
- 24 January 2023
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-11
Abstract
Mastocytosis is a very rare disorder and is divided into three prognostically distinct variants by World Health Organization: Cutaneous mastocytosis (CM), systemic mastocytosis (SM), and mast cell sarcoma or localized mast cell (MC) tumors. The wide range of complaints may cause patients to consult various clinics, with resulting mis- or underdiagnosis. Therefore, cooperation between different subspecialties is of paramount importance. In this article, we have compiled 104 adult mastocytosis cases diagnosed and followed in our Hematology and other clinics. 86 (82.7%) of 104 patients had systemic mastocytosis. Osteoporosis, disease-related complications, and secondary malignancies are important topics in this group. We know that indolent form has great survival. But smoldering or aggressive mastocytosis has a poor prognosis. CM and indolent SM have a significantly better prognosis compared to aggressive SM (p < 0.001). We found that the presence of more than 25% of mast cells in the bone marrow, the presence of concomitant marrow dysplasia, and the presence of disease-related complications affect survival (p < 0.001). In addition to the WHO classification, the IPSM scoring system is indicative of the prognosis in this rare disease.Keywords
All Related Versions
This publication has 33 references indexed in Scilit:
- Epidemiology of systemic mastocytosis in DenmarkBritish Journal of Haematology, 2014
- ASXL1 but Not TET2 Mutations Adversely Impact Overall Survival of Patients Suffering Systemic Mastocytosis with Associated Clonal Hematologic Non-Mast-Cell DiseasesPLOS ONE, 2014
- Hidden Mastocytosis in Acute Myeloid Leukemia With t(8;21)(q22;q22)American Journal of Clinical Pathology, 2013
- Prevalence of indolent systemic mastocytosis in a Dutch regionJournal of Allergy and Clinical Immunology, 2013
- International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosisBlood, 2013
- Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosisLaboratory Investigation, 2011
- Improved Detection of the KIT D816V Mutation in Patients with Systemic Mastocytosis Using a Quantitative and Highly Sensitive Real-Time qPCR AssayThe Journal of Molecular Diagnostics, 2011
- Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patientsJournal of Allergy and Clinical Immunology, 2009
- Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factorsBlood, 2009
- Cutaneous Mastocytosis in AdultsDermatology, 1998